PharmaLex Expands Integrated Market Access Expertise through Merger with MAP Group
PharmaLex Group has merged with MAP Group, broadening its market access expertise and extending its reach into the Italian marketplace.
PharmaLex Group has announced on Jan. 18, 2022, that is has merged with MAP Group, an Italian provider of market access services. Through this merger, PharmaLex broadens its market access expertise and extends its reach into the Italian marketplace.
MAP Group was founded in 2010 and comprises three companies—MA Provider, MAPCOM Consulting, and 3P Solution. The group specializes in highly innovative products, such as advanced therapeutic medicinal products (ATMPs) under development for rare diseases and oncology, and is a leading member of the ATMP forum.
“The merger with PharmaLex perfectly complements our service offerings by leveraging our strong local market knowledge and expertise while providing our clients with broader reach across Europe,” said Elena Paola Lanati, MAP Group CEO and founder, in the company press release. “We share common principles and values with PharmaLex, in particular to help our clients navigate an increasingly complex legislative and commercial marketplace. In addition, the merger with PharmaLex provides an opportunity for our talented people to expand their careers in a broader global marketplace.”
“We are delighted to welcome the MAP Group team to the PharmaLex Group, and we are excited about the opportunity that the merger gives us to further expand our offerings in market access, brand communications, and educational services,” added PharmaLex CEO Thomas Dobmeyer, in the press release. “The merger also enables us to extend our footprint in the important Italian marketplace, adding to our strong existing team in Milan, which provides regulatory, safety, and quality services to local clients. PharmaLex first established an office in Italy 2017 and has since built a strong local footprint. Through the merger with the MAP Group, we are further strengthening our team, allowing us to support clients throughout the product lifecycle in order to deliver exceptional, tailor-made results.”
Source: PharmaLex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
